The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate

This study was designed to investigate a long-term therapeutic strategy for the management of recurring atopic dermatitis (AD) in adults using fluticasone propionate (FP) ointment (Cutivate^TM) whereby FP could help to prevent a relapse of AD once symptoms were under control. Adult patients with chronic, moderate to severe AD entered this multicentre study. All patients were initially treated with FP 0.005% (g/g) ointment in two different regimens. Patients whose AD had been completely healed by these treatments then entered a long-term treatment phase applying FP or placebo ointment once daily, two times per week for 16 weeks to 'known' healed lesions. By the end of the initial treatment period, mean SCORAD values had significantly ( P  < 0.0005) improved from baseline. Patients who entered the maintenance phase and were treated with intermittent FP for up to 16 weeks, demonstrated its superior efficacy ( P  = 0.018) over placebo, maintaining the improvements achieved after the initial treatment phase, reducing risk of relapse and delaying time to relapse ( P  = 0.013). No significant changes were detected in either treatment group in serum cortisol levels or in skin thickness measurements. Intermittent FP applied two times per week maintained a significant level of control, and delayed relapse of AD by comparison with placebo.     

眶内游离真皮脂肪瓣填充矫正眼窝塌陷

我科近3年来对21例眼球摘除患者均Ⅰ期行自体游离真皮脂肪瓣眼窝填充以矫正眼窝塌陷,追踪观察1～2年,未发现填充物脱出、移位及缝线崩开,义眼活动度良好,眼睑外观饱满,现报道如下。 1　临床资料 　　本组21例,男13例,女8例。年龄最大52岁,最小16岁。眼球破裂伤9例,慢性眼内炎(视力丧失)7例,先天性眼球萎缩2例,角膜葡萄肿3例。本组病例均为Ⅰ期眼球摘除联合眶内游离真皮脂肪瓣填入术,效果满意。     

不同剂量低强度激光血管内照射对实验性糖尿病兔红细胞变形能力的影响及其时间效应

本研究首次采用了较大的功率和剂量（５ｍＷ、１０ｍＷ、１８ｍＷ和２５ｍＷ×６０ｍｉｎ）的Ｈｅ－Ｎｅ激光对实验性糖尿病新西兰兔进行了血管内照射，观察了其红细胞变形能力（ＲＣＤ）随剂量和时间的变化。结果发现：①在未实验所选用的功率和剂量范围内，大剂量的照射对ＲＣＤ的影响能较早地表现出来，且更持久。②在改善ＲＣＤ的程度上，剂量（功率）越大，则越表现出优越性，特别是在照射后第１天和第３天，剂量越大的组其平均ＩＦ指数越小。③而照射１２天以后各组无显著性差异，则说明一次照射不可能使ＲＣＤ彻底恢复正常，所以在临床应用时，应进行多次照射。④从照后各天结果的相互比较可以看出，第三天的效果最好，这一结果可为疗程设计提供参考。未次实验过程中未发现溶血现象。     

A novel mutation in MED12 causes FG syndrome (Opitz–Kaveggia syndrome)

Rump P, Niessen RC, Verbruggen KT, Brouwer OF, de Raad M, Hordijk R. A novel mutation in MED12 causes FG syndrome (Opitz–Kaveggia syndrome). Opitz–Kaveggia syndrome is a rare X‐linked multiple congenital anomalies and intellectual disability disorder caused by the recurrent p.R961W mutation in the MED12 gene. Twenty‐three affected males from 10 families with this mutation in the MED12 gene have been described so far. Here we report on a new family with three affected cousins, in which we identified a novel MED12 mutation (p.G958E). This is the first demonstration that other mutations in this gene can also lead to Opitz–Kaveggia syndrome. The clinical phenotype of these three new cases is reviewed in detail and compared with the previous reported cases.     

Nature of tumour rejection antigens in ovarian cancer

Major progress in the analysis of human immune responses to cancer has been made through the molecular characterization of human tumour antigens. The development of therapeutic strategies for eliciting immune‐mediated rejection of tumours has accelerated due to the elucidation of the molecular basis for tumour cell recognition and destruction by immune cells. Of the various human tumour antigens defined to date in ovarian cancer, the cancer‐testis (CT) family of antigens have been studied extensively preclinically and clinically because of their testis‐restricted expression in normal tissues and ability to elicit robust immune responses. Recent developments in cancer sequencing technologies offer a unique opportunity to identify tumour mutations with the highest likelihood of being expressed and recognized by the immune system. Such mutations, or neoantigens, could potentially serve as specific immune targets for T‐cell‐mediated destruction of cancer cells. This review will highlight current work in selecting tumour rejection antigens in ovarian cancer for improving the efficacy of immunotherapy.     

Recommendations on biosimilar low-molecular-weight heparins

Summary.  Based on the results of large clinical trials, several low-molecular-weight heparins (LMWHs) have been approved for prophylaxis and the treatment of venous and arterial thromboembolism. As a result of expiration or pending expiration of patent protection of the originator LMWHs, many generic or biosimilar LMWHs have been approved in some countries and more are likely to be approved elsewhere. Their greater availability may reduce the treatment costs. The Working Party on Requirements for Development of Biosimilar LMWHs of the Subcommittee on Control of Anticoagulation, Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis has reached a consensus on recommendations to ensure the quality of biosimilar LMWHs as compared with the originator LMWHs.